Mark J. Ahn
Direttore/Membro del Consiglio presso Chaminade University of Honolulu
Profilo
Mark J.
Ahn was the founder of Talon Therapeutics, Inc. (founded in 2003) where he served as President & Chief Executive Officer from 2003 to 2007.
He was also the founder of Aroa Biosurgery Ltd.
(founded in 2007) where he held the position of Director.
Currently, Dr. Ahn is a Director at Immusoft Corp., a Member-Governors Board at Chaminade University of Honolulu, and a Trustee at the University of South Africa (since 2010).
In his former positions, he served as President & Chief Executive Officer at Email Real Estate.com, Inc., President, Chief Executive Officer & Director at Galena Biopharma, Inc. (from 2012 to 2014), Vice Chairman at Abeona Therapeutics, Inc. (from 2015 to 2017), Senior Director-Immunology at Bristol Myers Squibb Co., Director at Essia Health, Inc., Director at TransMolecular, Inc., Director at Iovance Biotherapeutics, Inc. (from 2010 to 2011), and General Manager at Amgen, Inc. He also held the position of Vice President-Hematology & Corporate Officer at Genentech, Inc. (from 2001 to 2003), Associate Professor at Willamette University, and Principal at The Aspen Institute, Inc. Additionally, he was a Professor at Victoria University of Wellington (from 2007 to 2009) and Principal at Pukana Partners Ltd.
Dr. Ahn's education includes a graduate degree from Victoria University, undergraduate and MBA degrees from Chaminade University of Honolulu, and a doctorate degree from the University of South Australia.
Posizioni attive di Mark J. Ahn
Società | Posizione | Inizio |
---|---|---|
Chaminade University of Honolulu | Direttore/Membro del Consiglio | - |
University of South Africa | Direttore/Membro del Consiglio | 26/04/2010 |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Mark J. Ahn
Società | Posizione | Fine |
---|---|---|
ABEONA THERAPEUTICS INC. | Direttore/Membro del Consiglio | 09/01/2017 |
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Amministratore Delegato | 21/08/2014 |
IOVANCE BIOTHERAPEUTICS, INC. | Direttore/Membro del Consiglio | 07/02/2011 |
Victoria University of Wellington | Corporate Officer/Principal | 01/01/2009 |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Amministratore Delegato | 01/05/2007 |
Formazione di Mark J. Ahn
Victoria University | Graduate Degree |
Chaminade University of Honolulu | Masters Business Admin |
University of South Australia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 5 |
---|---|
AMGEN INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ABEONA THERAPEUTICS INC. | Health Technology |
AROA BIOSURGERY LIMITED | Health Technology |
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 9 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Email Real Estate.com, Inc. | Finance |
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
Essia Health, Inc.
Essia Health, Inc. Medical SpecialtiesHealth Technology Essia Health, Inc. provides EMR implementation services. Its services let healthcare providers focus on their patients while meeting essential technology requirements. The company was founded in 2011 by Kathleen M. Myers and is headquartered in Woodland Hills, CA. | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
The Aspen Institute, Inc.
The Aspen Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Aspen Institute operates an institution that fosters leadership skills and open-minded dialogue. It conducts seminars, policy programs, conferences and leadership development initiatives, the Institute and its international partners seek to promote nonpartisan inquiry. The company was founded in 1949 and is headquartered in Washington, DC. | Commercial Services |
Pukana Partners Ltd.
Pukana Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Pukana Partners Ltd. provides life sciences business consulting services. The private company is based in Portland, OR. | Commercial Services |
- Borsa valori
- Insiders
- Mark J. Ahn